Last updated: February 13, 2026
Litigation Summary and Analysis: Amarin Pharma Inc. v. West-Ward Pharmaceuticals Corp.
Case Overview
Amarin Pharma Inc. filed suit against West-Ward Pharmaceuticals Corp. (d/b/a West-Ward) in the District of Nevada, case number 2:16-cv-02525-MMD-NJK, on December 22, 2016. The lawsuit stems from allegations of patent infringement related to Amarin's intellectual property covering formulations and methods involving Vascepa (icosapent ethyl), a prescription fish oil medication approved by the FDA for reducing cardiovascular risk.
West-Ward responded with a timely non-infringement and invalidity defense, asserting that their generic version of Vascepa did not infringe Amarin’s patents and that the patents were invalid under patent law principles.
Patent Portfolio and Claims
Amarin's patent portfolio primarily includes U.S. Patent Nos. 8,618,177; 8,618,183; and 9,066,738, which claim formulations of icosapent ethyl and related methods for lowering triglycerides and reducing cardiovascular events.
The core patent claims cover specific formulations of EPA ethyl esters, with claimed purity levels, dosage regimes, and methods for decreasing triglycerides. These patents are slated to expire between 2027 and 2032, depending on the patent.
Litigation Timeline & Procedural Posture
- Initial Complaint (Dec. 2016): Amarin alleges that West-Ward’s proposed generic infringes the claims of the patents.
- Defenses and Motions: West-Ward filed motions for summary judgment, challenging both validity and infringement. Amarin countered with notices of infringement and motions for preliminary injunctions.
- Trial and Subsequent Proceedings: No jury trial has concluded publicly as of the latest information. The case has involved dispositive motions, claims construction hearings, and settlement discussions.
Key Legal Issues
- Infringement: Whether West-Ward’s generic products infringe Amarin’s patents under the doctrine of equivalents or literal infringement.
- Patent Validity: Challenges to patent validity based on prior art, obviousness, and written description.
- Patent Term & Market Exclusivity: The patents' remaining lifespan affects market dynamics, with litigation extending into the period of patent term.
Court Decisions & Rulings
As of the latest update, no final judgment has been publicly issued. The parties have engaged in extensive claim construction, with the court issuing a Markman opinion interpreting critical patent terms.
Amarin has sought injunctive relief, arguing that West-Ward's generic infringes valid patents, which, if granted, would block the launch of the generic product. West-Ward maintains that their product falls outside patent scope or that the patents are invalid.
Current Status & Outlook
- The case remains active, with ongoing discovery and motions.
- Settlement discussions are ongoing but have not resulted in resolution.
- The outcome hinges on the court’s findings regarding infringement and patent validity, which will influence the entry of generic competition.
Industry and Strategic Implications
The case exemplifies patent litigation in the highly competitive space of cardiovascular pharmaceuticals. A favorable ruling for Amarin could delay generic entry, maintaining exclusivity and high margins for Vascepa. Conversely, invalidation of key patents could accelerate generic competition, lowering prices and impacting revenue.
Key Takeaways
- Litigation centers on extensive patent claims covering formulations and methods related to Vascepa.
- The case exemplifies the strategic use of patent enforcement to control market entry.
- Patent validity arguments pose a significant risk; prior art references and obviousness challenges are common in such disputes.
- The unresolved status underscores the prolonged nature of patent litigation in pharmaceuticals.
FAQs
1. What is the primary legal dispute in the case?
The dispute focuses on whether West-Ward’s generic product infringes Amarin's patents and whether those patents are valid.
2. How could this lawsuit impact the market for Vascepa?
A court ruling in favor of Amarin could block generic entry until patents expire, while a ruling favoring West-Ward could enable earlier generic competition.
3. What are the main patents involved?
The key patents include U.S. Patent Nos. 8,618,177; 8,618,183; and 9,066,738, relating to formulations and methods involving EPA ethyl esters.
4. What legal strategies does Amarin employ?
Amarin relies on patent infringement claims and seeks injunctive relief, supported by claims construction, and patent validity arguments.
5. How long is the patent protection for Vascepa?
The patents are set to expire between 2027 and 2032, depending on the specific patent.
Sources
[1] Amarin Pharma Inc. v. West-Ward Pharmaceuticals Corp., 2:16-cv-02525-MMD-NJK, District of Nevada.
[2] U.S. Patent Nos. 8,618,177; 8,618,183; 9,066,738.
[3] Court filings and public case docket information, accessed February 2023.
[4] FDA Drug Approval database for Vascepa (2012).
